Trinity Biotech plc (TRIB) Fair Value 2026

TRIB · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (33/100)

Quick Summary — As of 2026-08-31, Trinity Biotech plc (TRIB) trades at $9.87. QOC: 4.8/10. Value Trap Risk: 33/100 (LOW). 0/13 models active.

Key Facts

Ticker
TRIB
Price
$9.87
Quality Score
4.8/10
Value Trap Risk
33/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.8/10 signals weak fundamentals

What Fair Value Does Each Model Give TRIB?

0 Intrinsic Value Models vs. Current Price ($9.87)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Trinity Biotech plc (TRIB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Trinity Biotech plc currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About TRIB?

0 of 13 models are currently active for TRIB. See which stocks rank higher →

How Does TRIB Rank in Medical Devices?

Among 159 Medical Devices stocks, TRIB ranks #130 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

As a biopharma enterprise, Trinity Biotech plc operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating TRIB should weigh these sector-specific dynamics alongside our model-derived fair values.

Is TRIB a Value Trap?

CirclFi's Value Trap algorithm assigns TRIB a score of 33/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Trinity Biotech plc. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Trinity Biotech plc's fundamental quality profile registers 4.8/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TRIB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Trinity Biotech plc Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

FEEDENvue Medical, Inc.QOC 4.8ALURAllurion Technologies Inc.QOC 4.8MBOTMicrobot Medical Inc.QOC 4.9AEMDAethlon Medical, Inc.QOC 4.7HSCSHeartSciences Inc.QOC 4.9RMSLREMSleep Holdings, Inc.QOC 4.6BSXBoston Scientific CorporationQOC 8.9ESTAEstablishment Labs Holdings Inc.QOC 7.0NMTCNeuroOne Medical Technologies CorporationQOC 6.1IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: FEED · ALUR · MBOT · AEMD · HSCS · RMSL · BSX · ESTA · NMTC · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to TRIB?

6 companies across all industries closest to TRIB’s Quality of Company score of 4.8/10.

SNGXSoligenix, Inc.QOC 4.8IVHIInvech Holdings, Inc.QOC 4.8GBUXGivBux, Inc.QOC 4.8TGLTreasure Global Inc.QOC 4.8OXSQOxford Square Capital Corp.QOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SNGX · IVHI · GBUX · TGL · OXSQ · NVDA

Where Does TRIB Sit in CirclFi's Medical Devices Rankings?

TRIB is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Trinity Biotech plc’s Valuation?

What is Trinity Biotech plc's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Trinity Biotech plc (TRIB). The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TRIB overvalued or undervalued right now?

At $9.87, 0 of 0 active models suggest TRIB may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Trinity Biotech plc's business model in Medical Devices.

What does a Quality of Company score of 4.8 mean for TRIB?

Trinity Biotech plc's QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on TRIB?

CirclFi analyzes TRIB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is TRIB a value trap in 2026?

Trinity Biotech plc's Value Trap score is 33/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Trinity Biotech plc (TRIB) a Quality of Company score of 4.8/10 across 32 fundamental signals as of 2026-08-31.” Source: circlfi.com/stock/TRIB/ · Methodology
Primary sources for this TRIB valuation
  • Financial statements: Trinity Biotech plc 10-K and 10-Q filings on SEC EDGAR (CIK 0000888721) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for TRIB as of ; valuations recomputed .